We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

GLP-1 Denied by Insurance? Appeal Steps and Cash-Pay Options

You did everything right. You talked to your provider, you started the paperwork, and then the letter came back: denied. It is a frustrating place to be, especially when you have already decided this is the step you want to take for your health. A denial is not always the end of the road. It usually comes down to one of a handful of specific reasons, and most of them have a next move. Here is how to read what happened, how to appeal if it makes sense, and what your options are if coverage still says no.

Transformation Health is an independent guide, not a provider: we do not prescribe, sell medication, or work with insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.

Why GLP-1 prescriptions get denied

A denial is not a judgment about whether you deserve treatment. It is the result of how your specific plan is written and how the request was processed. Knowing which reason applies to you matters, because each one points to a different next step.

Your plan excludes weight management medications. Some employer and individual plans carve out weight loss drugs entirely. If your plan has a categorical exclusion for this category, the medication is not a covered benefit for weight management, no matter how strong the clinical case is.

Prior authorization criteria were not met. Many plans require prior authorization for GLP-1 medications, meaning your prescriber has to submit clinical documentation before the plan will approve it. Plans do not publish a single denial rate, but some denials come back because something was missing from the submission rather than because you do not meet the plan’s criteria. Common gaps include a recent documented BMI, a weight-related condition that is not in the submitted records, or no record of prior lifestyle efforts. Many plans mirror the criteria for prescribing weight management medications: an adult BMI of 30 or higher, or 27 or higher with a weight-related health problem such as high blood pressure or type 2 diabetes.[1]

Step therapy requirements. Some plans use step therapy, which asks you to try one or more lower-cost options first and document that they did not work before they will approve a GLP-1.

The medication is non-formulary. If the specific medication is not on your plan’s formulary, or sits on a tier your plan does not cover for this use, the request can be denied on those grounds alone.

The denial notice should name the specific reason. That single detail is the most important thing on the page, because it tells you whether an appeal is worth pursuing and what to fix if it is.

Your first move: understand the denial and appeal

Before you do anything else, read the denial closely and figure out exactly why it was denied. From there, an appeal is often a reasonable next step.

Read the denial reason. Find the line that states why coverage was denied. A documentation gap is very different from a categorical exclusion. The first is often fixable; the second usually is not. The notice should also explain how to appeal and by when. HealthCare.gov says you must file an internal appeal within 180 days (6 months) of receiving the denial notice.[2]

Gather your documentation. If the denial points to missing or incomplete records, this is where you can make the most difference. Ask your prescriber’s office whether your recent BMI is documented from a visit, whether any weight-related conditions you have are in your chart, and whether prior diet and exercise efforts are recorded. Share only accurate records; what goes into the appeal is your prescriber’s call.

File an internal appeal. In an internal appeal, your insurer takes another look at its decision. HealthCare.gov says the decision is due within 30 days for a service you have not received yet, within 60 days for one you have already received, and within 4 business days if your situation is urgent.[2] Your prescriber’s office often handles the clinical side, but you may need to sign the request and provide your plan information. HealthCare.gov also notes that the Consumer Assistance Program in your state can file an appeal for you.[2]

Ask for an external review if the internal appeal fails. In many cases you can then ask for an independent external review, where an outside reviewer rather than your insurer decides. HealthCare.gov says you must file within 4 months of the notice or final determination, the decision is due no later than 45 days after the request (72 hours or less for urgent cases), and your insurer is required by law to accept the reviewer’s decision.[3] In urgent situations, you can ask for an external review at the same time as your internal appeal.[2]

Ask about an exception request. If the drug is not on your plan’s formulary, ask your plan how to request an exception. For individual and small-group plans that must cover essential health benefits, federal rules require a process for requesting a drug the plan does not otherwise cover; the plan must decide a standard request within 72 hours and a request based on urgent circumstances within 24 hours.[4]

For employer plans covered by the federal claims rule, a first decision on a request that needs approval in advance is due within 15 days (with one extension of up to 15 days allowed), or within 72 hours if the request is urgent.[5] These are outer limits, not predictions. Your plan documents state the exact limits that apply to you, and state-regulated, Medicare, and Medicaid plans have their own rules. If you have Medicare, see our page on Medicare Part D and GLP-1 coverage.

For a complete, step-by-step walkthrough of what insurers require and how each level of appeal works, see our guide on GLP-1 prior authorization.

This is general information, not legal advice, and every plan and state handles appeals a little differently. Your insurer’s member services line and your prescriber’s office are your best sources for the specifics of your case.

What to do if coverage is still no

Sometimes the answer stays no. The clearest example is a categorical exclusion for weight management medications, which an appeal generally cannot override. If that is your situation, or if you do not want to wait out a long appeal, here are the options to compare. There is no single right order; it depends on your plan, your health, and your budget.

  • A different covered use. Ask whether the medication is covered under a different FDA-approved indication that applies to you, such as type 2 diabetes. Your prescriber decides which medication and diagnosis fit your situation.
  • A different plan at open enrollment. If your employer offers more than one plan, or you buy your own coverage, check whether another plan covers GLP-1 medications for weight management, and compare its formulary and prior authorization rules before you switch.
  • Manufacturer savings cards and self-pay options. As of 2026-10-16, the Wegovy savings offer is for patients with commercial insurance and excludes government beneficiaries, and the Zepbound savings card requires a commercial drug plan and excludes people enrolled in government-funded programs such as Medicare, Medicaid, or VA coverage.[6][7] Lilly’s card terms include a version for people whose commercial drug plan does not cover the Zepbound KwikPen, which can matter after a denial.[7] Both manufacturers also list self-pay options that do not use insurance: Wegovy self-pay prescriptions are filled through NovoCare Pharmacy, with a price that varies by dose, and Lilly lists a Zepbound KwikPen self-pay offer through LillyDirect Pharmacy or another pharmacy.[6][7] Check each manufacturer’s current page for prices and terms. Our page on GLP-1 savings programs compares these options in more detail.
  • Cash-pay telehealth programs. These do not bill insurance, so there is no prior authorization step. Some prescribe brand-name medications; many prescribe compounded semaglutide or tirzepatide prepared by a compounding pharmacy.

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.[8] Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound, and they may differ in formulation, purity, and potency. A compounded medication is a separate path, not a swap for a covered brand-name drug, and whether it is appropriate for you is a decision for a licensed provider.

If you want the detailed cost picture, our page on compounded semaglutide cost explains what drives the price, and our guide to GLP-1 cost without insurance compares the routes.

The cash-pay path explained

A cash-pay program does not use insurance, so there is no prior authorization, no formulary to check, and no appeal to wait on. That does not make every program the same. Programs differ in what they charge for and what they include.

Prices vary by program and dose. Before you sign up, compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. Read the program’s terms for what the monthly fee covers, what is billed separately, and how cancellation works. Ask whether the program prescribes brand-name or compounded medication, and if compounded, which pharmacy prepares it.

You can also do both in parallel: keep an appeal or external review moving while you compare other options.

Transformation Health does not accept payment from providers. How we make money.

How the process should work

Because there is no insurance involved, the process is usually simpler than the prior authorization route you may have just been through.

At most cash-pay telehealth programs, you complete an online intake form covering your health history, a licensed provider reviews it and decides whether a prescription is appropriate, and if it is, the prescription goes to a pharmacy. Some states require a live video visit before certain prescriptions can be written; a program should tell you if that applies where you live.

If you have already started a GLP-1 through another route, tell the new prescriber what you have been taking and at what dose. Dose decisions are the prescriber’s call.

For more on this route, see our overview of how to get a prescription without insurance. You can also revisit the full insurance coverage section if you want to weigh your appeal options one more time before deciding.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

Sources

[1] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight and Obesity.” Accessed 2026-10-16. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

[2] HealthCare.gov (Centers for Medicare and Medicaid Services). “Internal appeals.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/

[3] HealthCare.gov (Centers for Medicare and Medicaid Services). “External review.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/

[4] 45 CFR 156.122(c) (prescription drug benefits: standard and expedited exception requests). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/45/156.122

[5] 29 CFR 2560.503-1(f)(2) (claims procedure for employee benefit plans: urgent care and pre-service claim decision deadlines). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/29/2560.503-1

[6] Novo Nordisk. “Save on Wegovy” (coverage and savings). Accessed 2026-10-16. https://www.wegovy.com/coverage-and-savings/save-on-wegovy.html

[7] Eli Lilly and Company. “Zepbound Coverage and Savings.” Accessed 2026-10-16. https://zepbound.lilly.com/coverage-savings

[8] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Important disclosures

The information on this page about insurance denials, prior authorization, step therapy, exceptions, and appeals is general and educational. It does not represent the terms of your specific plan and is not legal advice. Coverage rules and appeal procedures vary by insurer, by plan type, and by state. For details on your own situation, contact your insurer’s member services line and your prescriber’s office.

Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, does not bill insurance, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound, and they may differ in formulation, purity, and potency. Manufacturer savings program eligibility and terms change frequently; check manufacturer websites directly for current information. Insurance and appeal information is general and does not represent your specific plan; confirm current details and deadlines with your plan. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
Why was my GLP-1 denied by insurance?
Common reasons include a plan that excludes weight management medications entirely, prior authorization criteria that were not met (sometimes a documentation gap), step therapy that requires trying other options first, or the medication being non-formulary on your plan. Read the denial notice closely; it should state the specific reason, which shapes what to do next.
Can I appeal a GLP-1 denial?
In most cases, yes. HealthCare.gov says you can ask your insurer for an internal appeal within 180 days of the denial notice, and if that does not succeed, you can in many cases ask for an external review by an independent reviewer. An appeal has a better chance when the denial points to missing or unclear documentation your prescriber can supply, and a lower chance when the plan excludes weight management drugs as a category.
How long does a GLP-1 appeal take?
HealthCare.gov says an internal appeal for a service you have not received yet must be decided within 30 days, and an urgent appeal within 4 business days. If you then ask for an external review, the decision is due within 45 days, or 72 hours or less for urgent cases. These are federal outer limits; state-regulated, Medicare, and Medicaid plans have their own rules, and your plan documents state the exact limits that apply to you.
What are my options if the appeal fails?
Options to look into include: whether the medication is covered under a different FDA-approved indication that applies to you, such as type 2 diabetes; an external review if you have not used one; a different plan at your next open enrollment; a manufacturer savings or self-pay option; or a cash-pay telehealth program. Prices vary by program and dose, so compare the total cost before you choose.
Can I get a GLP-1 without insurance?
Yes, if a licensed provider decides a prescription is appropriate for you. Manufacturer self-pay options and cash-pay telehealth programs do not go through insurance. At most telehealth programs, a licensed provider reviews your health history and decides whether to prescribe. Some programs prescribe compounded medications, which are not FDA-approved; the FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.